Trial Profile

A Safety and Tolerability Study of ENC-201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENC 201 (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; First in man
Sponsors Encellin

Most Recent Events

06 May 2024 Status changed from planning to recruiting.
18 Dec 2023 New trial record
13 Dec 2023 According to Encellin media release, the company announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator, The new funding will advance a Phase 1 clinical trial evaluating subcutaneous transplantation of primary islets within Encellins EnCRT in T1D. First-in-human data from the Phase 1 study is expected next year

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com